S&P 500
(0.80%) 5 277.51 points

Dow Jones
(1.51%) 38 686 points

Nasdaq
(-0.01%) 16 735 points

Oil
(-0.94%) $77.18

Gas
(0.35%) $2.58

Gold
(-0.79%) $2 347.70

Silver
(-3.10%) $30.56

Platinum
(0.63%) $1 044.50

USD/EUR
(-0.17%) $0.921

USD/NOK
(-0.49%) $10.49

USD/GBP
(-0.05%) $0.785

USD/RUB
(0.15%) $90.40

Realtime updates for Prothena Corporation PLC [PRTA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

BUY

75.00%
return 3.18%

SELL

60.00%
return -1.66%

Last Updated31 May 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

2.97% $ 20.81

BUY 155239 min ago

@ $27.01

Issued: 14 Feb 2024 @ 15:42

Return: -22.95%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -1.57 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States...

Stats
Today's Volume	524 003
Average Volume	536 595
Market Cap	1.12B
EPS	$0 ( 2024-05-08 )
Next earnings date	( $-1.220 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.48
ATR14	$0.0280 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Welch Daniel G	Buy	15 000	Stock Option (Right to Buy)
2024-05-15	Selkoe Dennis J.	Buy	15 000	Stock Option (Right to Buy)
2024-05-15	Kim Helen Susan	Buy	15 000	Stock Option (Right to Buy)
2024-05-15	Ekman Lars	Buy	15 000	Stock Option (Right to Buy)
2024-05-15	Dunn William H. Jr.	Buy	15 000	Stock Option (Right to Buy)

INSIDER POWER
81.45
Last 98 transactions
Buy: 1 295 000 \| Sell: 174 000

Volume Correlation

Long: 0.30 (neutral)

Short: 0.85 (strong)

Signal:(70.52) Same movement expected

Prothena Corporation PLC Correlation

10 Most Positive Correlations
CLNE	0.948
VVOS	0.947
INVZ	0.945
ASLE	0.944
LGVN	0.941
AEHR	0.936
DCFC	0.935
TSLA	0.935
EVOK	0.934
WW	0.934

10 Most Negative Correlations
ADTH	-0.926
APXI	-0.917
ESTA	-0.913
KINS	-0.912
INBKZ	-0.906
GHRS	-0.905
KRUS	-0.904
BSCO	-0.902
SWAV	-0.902
DXJS	-0.9

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Prothena Corporation PLC Correlation - Currency/Commodity

-0.45
( neutral )

-0.37
( neutral )

0.00
( neutral )

-0.41
( neutral )

-0.08
( neutral )

0.23
( neutral )

Prothena Corporation PLC Financials

Annual	2023
Revenue:	$91.37M
Gross Profit:	$82.96M (90.79 %)
EPS:	$-2.76

FY	2023
Revenue:	$91.37M
Gross Profit:	$82.96M (90.79 %)
EPS:	$-2.76

FY	2022
Revenue:	$53.91M
Gross Profit:	$47.16M (87.49 %)
EPS:	$-2.47

FY	2021
Revenue:	$200.58M
Gross Profit:	$0.00 (0.00 %)
EPS:	$1.510

Financial Reports:

No articles found.

Prothena Corporation PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Prothena Corporation PLC

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.

Total Execution Time: 1.7073650360107 seconds
Number of API calls: 2
Number of DB calls: 8